Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nurix Therapeutics

11.49
-0.1300-1.12%
Post-market: 11.490.00000.00%17:10 EDT
Volume:1.48M
Turnover:17.04M
Market Cap:875.95M
PE:-4.10
High:11.88
Open:11.73
Low:11.22
Close:11.62
Loading ...

Analysts Conflicted on These Healthcare Names: Align Tech (ALGN), Nurix Therapeutics (NRIX) and Thermo Fisher (TMO)

TIPRANKS
·
17 Jun

Oppenheimer Remains a Buy on Nurix Therapeutics (NRIX)

TIPRANKS
·
16 Jun

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
14 Jun

Truist Financial Keeps Their Buy Rating on Nurix Therapeutics (NRIX)

TIPRANKS
·
13 Jun

RBC Raises Price Target on Nurix Therapeutics to $28 From $27, Keeps Outperform, Speculative Risk

MT Newswires Live
·
13 Jun

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX) and Telix Pharmaceuticals (OtherTLPPF)

TIPRANKS
·
13 Jun

Nurix Therapeutics presents updated data from ongoing trial of bexobrutideg

TIPRANKS
·
12 Jun

Nurix Therapeutics Inc - Bexobrutideg Well Tolerated With No New Safety Signals

THOMSON REUTERS
·
12 Jun

Nurix Therapeutics Inc - Reports 80.9% Orr in Cll, 84.2% in Wm Patients

THOMSON REUTERS
·
12 Jun

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (Nx-5948) Monotherapy in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (Cll) and WaldenstrÖM Macroglobulinemia (Wm)

THOMSON REUTERS
·
12 Jun

Nurix Therapeutics Inc - to Initiate Pivotal Trials of Bexobrutideg in 2025

THOMSON REUTERS
·
12 Jun

Oppenheimer Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)

TIPRANKS
·
11 Jun

Truist Financial Sticks to Its Buy Rating for Nurix Therapeutics (NRIX)

TIPRANKS
·
09 Jun

Leerink Partners Sticks to Its Hold Rating for Nurix Therapeutics (NRIX)

TIPRANKS
·
03 Jun

Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Sanofi (SNYNF)

TIPRANKS
·
02 Jun

Nurix Therapeutics Stock Climbs as Sanofi Extends License for STAT6

Dow Jones
·
02 Jun

Oppenheimer bullish on Nurix as Sanofi opt-in, competitor data derisk STAT6

TIPRANKS
·
02 Jun

Analyst Recommends ‘Buy’ for Nurix Therapeutics Amid Strong Endorsement and Promising STAT6 Program

TIPRANKS
·
02 Jun

BRIEF-Sanofi Exercises License Extension Option To Nurix’S Stat6 Program

Reuters
·
02 Jun

Nurix Therapeutics Inc - to Receive $15 Mln License Extension Fee From Sanofi

THOMSON REUTERS
·
02 Jun